Annual report pursuant to Section 13 and 15(d)

Strategic Alliances Strategic Alliances (Details)

v2.4.1.9
Strategic Alliances Strategic Alliances (Details) (USD $)
12 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2010
Dec. 31, 2014
Jan. 31, 2015
Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenue from sale of intellectual property $ 0opk_RevenueFromSaleOfIntellectualProperty $ 12,500,000opk_RevenueFromSaleOfIntellectualProperty $ 0opk_RevenueFromSaleOfIntellectualProperty        
TESARO              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Payments under license agreements       121,000,000opk_PaymentsUnderLicenseAgreements
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_TesaroMember
     
Up front payment under license agreements       6,000,000opk_LicenseAndCollaborationAgreementsProceedsAsUpFrontPayment
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_TesaroMember
     
TESARO | Collaborative Arrangement              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Milestone payment received         5,000,000opk_CollaborativeArrangementMilestonePaymentReceived
/ us-gaap_CounterpartyNameAxis
= opk_TesaroMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
Merck              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Additional milestone payment to Merck 25,000,000opk_CollaborativeAgreementAdditionalMilestonePayment
/ us-gaap_CounterpartyNameAxis
= opk_MerckMember
           
Merck | Collaborative Arrangement              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Milestone payment to Merck         2,000,000opk_CollaborativeArrangementMilestonePaymentPaid
/ us-gaap_CounterpartyNameAxis
= opk_MerckMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
In-process research and development expense         2,000,000us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
/ us-gaap_CounterpartyNameAxis
= opk_MerckMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
Additional milestone payment to Merck         25,000,000opk_CollaborativeAgreementAdditionalMilestonePayment
/ us-gaap_CounterpartyNameAxis
= opk_MerckMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
RXi Pharmaceuticals Corporation              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenue from sale of intellectual property   12,500,000opk_RevenueFromSaleOfIntellectualProperty
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_RxiPharmaceuticalsCorporationMember
         
Estimated milestone payments             50,000,000opk_EquityMethodInvestmentEstimatedMilestonePaymentsToBeReceived
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_RxiPharmaceuticalsCorporationMember
Subsequent Event | Pfizer Inc. | Collaborative Arrangement, Product              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Non-refundable and non-creditable payment to be received           295,000,000opk_CollaborativeArrangementUpfrontPayment
/ us-gaap_CounterpartyNameAxis
= opk_PfizerInc.Member
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementProductAgreementMember
 
Additional milestone payment to be received           $ 275,000,000opk_CollaborativeArrangementMaximumMilestonePayments
/ us-gaap_CounterpartyNameAxis
= opk_PfizerInc.Member
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementProductAgreementMember